Deferred revenue recognized
Pfizer·Products & Services·1 segment·Rolls up to Revenue recognized that was included in deferred income at the beginning of the period
Breakdown
Segments
Paxlovid and ComirnatyView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Paxlovid and Comirnaty | $200M | $1.1B | $600M | $335M | $45M | $96M | $295M | $58M |
| Total | — | — | — | — | — | — | — | — |